The assessment of PTEN tumor suppressor gene in combination with Gleason scoring and serum PSA to evaluate progression of prostate carcinoma
- 1 July 2004
- journal article
- clinical trial
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 22 (4) , 307-312
- https://doi.org/10.1016/j.urolonc.2004.01.009
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- State-of-the-Art Treatment of Metastatic Hormone-Refractory Prostate CancerThe Oncologist, 2002
- Hormone Therapy for Locally Advanced Prostate CancerJournal of Urology, 2002
- Molecular basis of co-targeting prostate tumor and stromaJournal of Cellular Biochemistry, 2002
- Prognostic markers inprostate cancerExpert Review of Molecular Diagnostics, 2002
- Loss of p53 and c-myc Overrepresentation in Stage T2-3N1-3M0 Prostate Cancer are Potential Markers for Cancer ProgressionLaboratory Investigation, 2002
- Lipopolysaccharide Induces Rac1-dependent Reactive Oxygen Species Formation and Coordinates Tumor Necrosis Factor-α Secretion through IKK Regulation of NF-κBJournal of Biological Chemistry, 2001
- Discrepancy between Gleason Scores of Biopsy and Radical Prostatectomy SpecimensEuropean Urology, 2000
- Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancersNature Genetics, 1997
- Staging of prostate cancerSeminars in Surgical Oncology, 1994
- The TNM classification of prostate cancerThe Prostate, 1992